<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Zolmitriptan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Zolmitriptan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Zolmitriptan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11156" href="/d/html/11156.html" rel="external">see "Zolmitriptan: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="108666" href="/d/html/108666.html" rel="external">see "Zolmitriptan: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24520479"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zomig;</li>
<li>Zomig ZMT [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868649"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Zolmitriptan Rapid [DSC];</li>
<li>APO-Zolmitriptan [DSC];</li>
<li>AURO-Zolmitriptan;</li>
<li>BIO-Zolmitriptan;</li>
<li>CCP-Zolmitriptan [DSC];</li>
<li>JAMP Zolmitriptan;</li>
<li>JAMP-Zolmitriptan;</li>
<li>JAMP-Zolmitriptan ODT;</li>
<li>MINT-Zolmitriptan;</li>
<li>NAT-Zolmitriptan;</li>
<li>NRA-Zolmitriptan;</li>
<li>PMS-Zolmitriptan ODT;</li>
<li>PMS-Zolmitriptan [DSC];</li>
<li>SANDOZ Zolmitriptan;</li>
<li>SANDOZ Zolmitriptan ODT;</li>
<li>TEVA-Zolmitriptan;</li>
<li>TEVA-Zolmitriptan OD;</li>
<li>Zomig;</li>
<li>Zomig Rapimelt</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F236106"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimigraine Agent;</li>
<li>
                        Serotonin 5-HT<sub>1B, 1D</sub> Receptor Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F236074"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="14b1efae-5801-4f12-9745-24f30c221671">Cluster headache, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cluster headache, treatment (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Limit use to &lt;10 days per month to avoid medication-overuse headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>). Intranasal route preferred due to shorter onset of action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10802793','lexi-content-ref-17724283','lexi-content-ref-33948734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10802793','lexi-content-ref-17724283','lexi-content-ref-33948734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal:</b> 5 to 10 mg as a single dose at the onset of cluster headache, administered in nostril contralateral to side of headache (maximum single dose: 10 mg). May repeat once if needed after ≥2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16966497','lexi-content-ref-May.1','lexi-content-ref-17724283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16966497','lexi-content-ref-May.1','lexi-content-ref-17724283'])">Ref</a></span>). <b>Note:</b> Nasal inhalation available as a 2.5 or 5 mg dose per nasal sprayer.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 to 10 mg as a single dose at the onset of cluster headache (maximum single dose: 10 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10802793']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10802793'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70ffddf9-14fd-433a-9492-6280ee72bf79">Menstrual migraine, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Menstrual migraine, prophylaxis (off-label use):</b>
<b>Oral:</b> 2.5 mg 2 to 3 times daily starting 2 days prior to the expected onset of menses and continued through to 5 days after the onset of menses (7 days total) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18788838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18788838'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d36d256f-8d0c-47cc-acaf-2f0f3747bed4">Migraine, moderate to severe, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Do <b>not</b> use within 24 hours of an ergotamine preparation or a different triptan. Limit use to &lt;10 days per month to avoid medication-overuse headache. Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment. When attack is complicated by severe nausea or vomiting, a nonoral preparation may be more effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 mg as a single dose; if symptoms persist or return, may repeat dose after ≥2 hours. The manufacturer's labeling recommends a single dose of 1.25 or 2.5 mg; however, some experts recommend 2.5 mg based on efficacy data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23968886','lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23968886','lexi-content-ref-31113373'])">Ref</a></span>). Maximum: 5 mg/dose; 10 mg per 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24848613','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24848613','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal: </b>2.5 to 5 mg as a single dose; if symptoms persist or return, may repeat dose after ≥2 hours. Maximum: 5 mg/dose; 10 mg per 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15697326','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15697326','lexi-content-ref-Manu.1'])">Ref</a></span>).<b> Note: </b>Some experts recommend a large initial dose, as it may be more effective than multiple smaller doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373','lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373','lexi-content-ref-Schwedt.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991589"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling; however, zolmitriptan clearance is reduced in patients with severe renal impairment (CrCl 5 to 25 mL/minute).</p></div>
<div class="block doha drugH1Div" id="F50988776"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: There is no dosage adjustment provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment: Initial: 1.25 mg (maximum: 5 mg per 24 hours in severe impairment).</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: There is no dosage adjustment provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal inhalation:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Moderate to severe impairment: Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F236075"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Initiate therapy at the low end of the dosing range.</p></div>
<div class="block dop drugH1Div" id="F52812468"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="108666" href="/d/html/108666.html" rel="external">see "Zolmitriptan: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c5d22a7-6932-4862-ad9b-086c6c9df805">Migraine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine:</b> Children ≥12 years and Adolescents: Intranasal: Nasal inhalation:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose:</i> 2.5 mg; may titrate as individual response may vary; maximum single dose: 5 mg/dose; <b>Note:</b> Administer at the onset of migraine headache.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Second dose:</i> May repeat in 2 hours if the migraine headache has not resolved or returns after transient improvement; maximum daily dose: 10 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51196066"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, zolmitriptan clearance is reduced in patients with severe renal impairment (CrCl 5 to 25 mL/minute).</p></div>
<div class="block dohp drugH1Div" id="F51196067"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Nasal inhalation: Children ≥12 years and Adolescents: Not recommended in patients with moderate or severe hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F236036"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Unpleasant taste (nasal: adults: 17% to 21%; children &amp; adolescents: 6% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (oral: 2% to 4%), chest pressure (nasal: 1% to &lt;2%), facial edema (nasal: 1% to &lt;2%), palpitations (nasal: 1% to &lt;2%), cardiac arrhythmia (≤1%), hypertension (≤1%), syncope (≤1%), tachycardia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (adults: 6% to 10%; children &amp; adolescents: 2%), paresthesia (5% to 10%), drowsiness (4% to 8%), local alterations in temperature sensations (oral: 5% to 7%), sensation of pressure (oral: 2% to 5%), hyperesthesia (nasal: 1% to 5%), (1% to 5%), flushing sensation (nasal: 4%), pain (nasal: 2% to 4%), vertigo (oral: 2%), chills (nasal: 1% to &lt;2%), depersonalization (nasal: 1% to &lt;2%), headache (1% to &lt;2%), agitation (≤1%), amnesia (≤1%), anxiety (≤1%), depression (≤1%), emotional lability (oral: ≤1%), insomnia (≤1%), nervousness (nasal: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (oral: 2% to 3%), pruritus (≤1%), skin rash (≤1%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (adults: 4% to 9%; children &amp; adolescents: 2%), xerostomia (2% to 5%), dyspepsia (oral: 2% to 3%), dysphagia (1% to 2%), abdominal pain (nasal: 1% to &lt;2%), vomiting (1% to &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (oral: ≤1%), urinary urgency (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local pain (4% to 10%; neck/throat/jaw), application site irritation (nasal: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (oral: 5% to 9%; nasal: 3%), arthralgia (nasal: 1% to &lt;2%), myalgia (nasal: 1% to &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal discomfort (nasal: 3%), constriction of the pharynx (nasal: 2%), pressure on pharynx (nasal: 1% to &lt;2%), bronchitis (nasal: ≤1%), cough (nasal: ≤1%), dyspnea (nasal: ≤1%), epistaxis (nasal: ≤1%), laryngeal edema (nasal: ≤1%), pharyngitis (nasal: ≤1%), rhinitis (nasal: ≤1%), sinusitis (nasal: ≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, abnormality in thinking, altered sense of smell, amblyopia, anaphylactoid reaction, anaphylaxis, angina pectoris, angioedema, apathy, ataxia, atrial fibrillation, back pain, bradycardia, breast carcinoma, breast neoplasm, bruise, cellulitis, cerebral ischemia, colitis, confusion, conjunctivitis, constipation, convulsions, coronary artery vasospasm, cyanosis, cyst, cystitis, diarrhea, dry eye syndrome, dysmenorrhea, eczema, eructation, erythema, erythema multiforme, euphoria, eye pain, fever, fibrocystic breast disease, flu-like symptoms, gastritis, gastrointestinal carcinoma, gastrointestinal infarction, gastrointestinal necrosis, genitourinary neoplasm, gingivitis, hallucination, hepatic neoplasm, hiccups, hypertensive crisis, hyperthyroidism, hypertonia, hyperventilation, increased appetite, increased bronchial secretions, increased thirst, infection, intestinal obstruction, irritability, ischemic colitis, ischemic heart disease, lacrimation, laryngitis, leukopenia, mania, menorrhagia, myocardial infarction, neoplasm, neuropathy, otalgia, photophobia, pneumonia, psychosis, pyelonephritis, renal pain, salivation, seizure, serotonin syndrome, sialadenitis, skin neoplasm, splenic infarction, stomatitis, tardive dyskinesia, tenosynovitis, thrombophlebitis, thyroid edema, tongue edema, tremor, twitching, urinary tract infection, uterine fibroid enlargement, uterine hemorrhage, vaginitis, vasodilation, ventricular fibrillation, ventricular tachycardia, visual field defect, voice disorder, yawning</p></div>
<div class="block coi drugH1Div" id="F236050"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to zolmitriptan or any component of the formulation; ischemic coronary artery disease (angina pectoris, history of myocardial infarction [MI], or documented silent ischemia); coronary artery vasospasm, including Prinzmetal variant angina, or other significant underlying cardiovascular disease; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; recent use (within 24 hours) of another 5-HT<sub>1</sub> agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide; history of stroke, transient ischemic attack, or history of hemiplegic migraine or migraine with brainstem aura; coadministration of monoamine oxidase A (MAO A) inhibitors or use of zolmitriptan within 2 weeks of discontinuation of MAO A inhibitor therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Valvular heart disease; ophthalmoplegic migraine.</p></div>
<div class="block war drugH1Div" id="F236033"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported within a few hours of 5-HT<sub>1</sub> agonist administration. Consider administering first dose in a medically supervised setting with ECG monitoring for patients with multiple risk factors for atherosclerotic cardiovascular disease (ASCVD) (eg, diabetes, hypertension, increased age, obesity, smoking, strong family history of ASCVD), but only after a cardiovascular evaluation that is satisfactory to allow for safe use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT<sub>1</sub> agonist administration and some have resulted in fatalities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasospasm-related events: Peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction (presenting with abdominal pain and bloody diarrhea), splenic infarction, and Raynaud syndrome have been reported with 5-HT<sub>1</sub> agonists. In patients who experience signs or symptoms suggestive of a vasospastic reaction following use of a 5-HT<sub>1</sub> agonist, rule out a vasospastic reaction before receiving additional doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual effects: Rarely, partial vision loss and blindness (transient and permanent) have been reported with 5-HT<sub>1</sub> agonists.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Coronary artery disease: Should not be given to patients who have risk factors for ASCVD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of ASCVD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected ASCVD should have cardiovascular evaluation to rule out ASCVD before considering use; if cardiovascular evaluation is satisfactory and clinicians determine that it is safe to proceed with use, first dose should be given in the health care provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Drug clearance may be reduced leading to increased plasma concentrations. With moderate to severe hepatic impairment, dosage reduction of the oral product is recommended; use of orally disintegrating tablet and nasal inhalation are not recommended in moderate to severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Older adult patients are more likely to have underlying cardiovascular disease and hepatic or renal impairment; use with caution. Cardiovascular evaluation is recommended for older adult patients with other cardiovascular risk factors prior to initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Zomig-ZMT tablets contain phenylalanine.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878678"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Serious adverse events have been reported with triptans in pediatric patients, including zolmitriptan; like adults, those reported have been rare and similar in nature.</p></div>
<div class="block foc drugH1Div" id="F236043"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig: 2.5 mg (6 ea); 5 mg (6 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg (6 ea [DSC]); 5 mg (1 ea, 6 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig: 2.5 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig ZMT: 2.5 mg [DSC], 5 mg [DSC] [contains aspartame; orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F236029"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F236052"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ZOLMitriptan Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $105.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Zomig Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $117.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $117.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (ZOLMitriptan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $50.13 - $55.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $55.42 - $61.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (ZOLMitriptan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $1.40 - $55.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.40 - $61.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zomig Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $155.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $155.23</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868650"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig: 2.5 mg (2 ea); 5 mg (6 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig: 2.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zomig Rapimelt: 2.5 mg [contains aspartame]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg</p></div>
<div class="block adm drugH1Div" id="F236047"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: May be broken in half to achieve a smaller initial dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Must be taken whole; do not break, crush, or chew. Place on tongue and allow to dissolve. Administration with liquid is not required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Nasal spray: Each nasal spray unit contains one dose; to avoid losing dose, do not prime device or press plunger before inserted in nostril. Remove unit from package immediately prior to use. Blow nose gently prior to use. After removing protective cap, instill device into nostril. Block opposite nostril; using other hand, with thumb supporting bottom of unit and index and middle fingers on either side of nozzle, insert nozzle as far into nostril as comfortable; tilt head slightly back. Breathe in gently through nose while pressing plunger of spray device. Breathe gently through mouth for 5 to 10 seconds.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Cluster headache (off-label use):</b> Administer in nostril contralateral to side of headache (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16966497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16966497'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52614035"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Administer as soon as migraine headache starts.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal spray: Blow nose gently prior to use. After removing protective cap, instill device into nostril, tilt head back slightly. Block opposite nostril; breathe in gently through nose while pressing plunger of spray device. Breathe gently through mouth for 5 to 10 seconds.</p></div>
<div class="block use drugH1Div" id="F236046"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, moderate to severe, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Nasal inhalation: Acute treatment of migraine with or without aura in adults and pediatric patients ≥12 years.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Acute treatment of migraine with or without aura in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use:</p>
<p style="text-indent:-2em;margin-left:4em;">• Not indicated for migraine prophylaxis according to manufacturer labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Not indicated for treatment of cluster headache according to manufacturer labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Use only if a clear diagnosis of migraine has been established.</p></div>
<div class="block off-label drugH1Div" id="F25468918"><span class="drugH1">Use: Off-Label: Adult</span><p>Cluster headache, treatment; Menstrual migraines (short-term prevention)</p></div>
<div class="block mst drugH1Div" id="F236114"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ZOLMitriptan may be confused with SUMAtriptan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F236100"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F236038"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the adverse/toxic effect of Serotonin 5-HT1D Receptor Agonists (Triptans). Management: Consider alternatives to this combination when possible. If combined, monitor for increased bromocriptine and triptan toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of ZOLMitriptan. Management: Limit the maximum single dose of zolmitriptan to 2.5 mg, not to exceed 5 mg in 24 hours, when coadministered with cimetidine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Monoamine Oxidase Inhibitors may increase the serum concentration of Serotonin 5-HT1D Receptor Agonists (Triptans). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Serotonin 5-HT1D Receptor Agonists (Triptans) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the vasoconstricting effect of other Serotonin 5-HT1D Receptor Agonists (Triptans).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F236053"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal use of zolmitriptan during pregnancy are limited in comparison to other 5-HT<sub>1B/1D</sub> agonists (triptans) (Källén 2011; Nezvalová-Henriksen 2010; Nezvalová-Henriksen 2012; Nezvalová-Henriksen 2013; Spielmann 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Triptans relieve migraine pain by selectively binding to serotonin receptors, resulting in vasoconstriction of cranial arteries. Although the effects on uterine blood flow have not been evaluated, 1 case report suggests excessive use of a triptan may cause placental hypoperfusion (ACOG 2022; Viard 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). Triptans are not the preferred initial treatment for acute migraine headache in pregnant patients (ACOG 2022). Until additional data are available, zolmitriptan is not the preferred triptan when first-line therapy is ineffective. Triptans should be avoided in pregnant patients with cardiac disease or hypertension (ACOG 2022; CHS [Worthington 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Acute treatment of cluster headache in pregnant patients is similar to nonpregnant adults; however, zolmitriptan is not preferred when a triptan is needed (AHS [Robbins 2016]; Bjørk 2021; Schindler 2022).</p></div>
<div class="block brc drugH1Div" id="F18881624"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Zolmitriptan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of 5-HT<sub>1B/1D</sub> agonists (triptans) in breast milk is available from a study of 19 lactating women (6 weeks to 30 months postpartum) treated for migraine headaches. During the study, infants were fed previously expressed breast milk. Breast milk was sampled prior to and at intervals up to 24 hours after the dose in patients taking zolmitriptan 5 mg (nasal spray, n=1) or 2.5 mg (orally, n=3). Using the average breast milk concentration observed, authors of the study calculated the estimated exposure of zolmitriptan to the breastfed infant to be 0.6 mcg/kg/day, providing a relative infant dose (RID) of 0.7% based on the weight-adjusted maternal dose following use of the nasal spray. Following maternal use of oral zolmitriptan, the estimated exposure to the breastfed infant was calculated to be 0.2 to 1.5 mcg/kg/day (RID 0.8% to 5.3%). Using the maximum breast milk concentration, the RID of zolmitriptan was calculated to be 1.4% to 9.4%. The active metabolite of zolmitriptan was not included in the calculations (concentrations were near or below the limit of quantification). One patient was also taking propranolol for migraine headache prevention; her Cmax and AUC were higher than other patients taking zolmitriptan. A large interindividual variability among breast milk concentrations was found with all the triptans in the study, even when considering dose and dosage form (Amundsen 2021). In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment for migraine headaches in breastfeeding patients should be individualized (AHS [Ailani 2021]). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Withholding breastfeeding for 24 hours after the maternal dose will minimize infant exposure via breast milk. The decision to withhold breastfeeding following a dose of zolmitriptan should be part of a shared decision-making process (ACOG 2022).</p></div>
<div class="block dic drugH1Div" id="F9738958"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F22904505"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP; cardiovascular evaluation (prior to initiation and periodically with long-term use in patients with multiple risk factors for atherosclerotic cardiovascular disease [ASCVD] [eg, diabetes, hypertension, increased age, obesity, smoking, strong family history of ASCVD]), ECG (with first dose in patients with multiple ASCVD risk factors, but a cardiovascular evaluation that is satisfactory to allow for safe use).</p></div>
<div class="block pha drugH1Div" id="F236032"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) in cranial arteries and sensory nerves of the trigeminal system; causes vasoconstriction and reduces inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>
<div class="block phk drugH1Div" id="F236049"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Tablet: ~30 minutes to 1 hour (Bahra 2000; Rapoport 1997); Orally disintegrating tablet: ~30 minutes to 1 hour (Dowson 2002; Spierings 2004); Nasal spray: ~10 minutes (Gawel 2005; Rapoport 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Oral: 7 L/kg; Nasal spray: 8.4 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 25%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Converted to an active N-desmethyl metabolite (2-6 times more potent than zolmitriptan at 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 40% (not impacted by food); mean bioavailability of nasal spray compared with oral tablet: 102%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Tablet: 1.5 hours; Orally disintegrating tablet and nasal spray: 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60% to 65% total dose; 8% of total dose as unchanged drug; 4% of total dose as N-desmethyl metabolite); feces (30%).</p></div>
<div class="block phksp drugH1Div" id="F51192023"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance of oral zolmitriptan was reduced 25% in patients with severe renal impairment (CrCl 5 to 25 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In severely hepatically impaired patients, the C<sub>max</sub>, T<sub>max</sub>, and AUC were increased 1.5-, 2-, and 3-fold, respectively, when dosed orally.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Mean plasma concentrations of oral zolmitriptan were up to 1.5-fold higher in women than men.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F236054"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Jubitran odt | Zomig</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zomigon</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aurasin akut | Zolmitriptan 1a pharma | Zolmitriptan stada | Zomig</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo zolmitriptan | Zoltrip | Zomig</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Miotrol | Nomi | Zolmit | Zomitan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan eg | Zolmitriptan odis mylan | Zolmitriptan sandoz | Zolmitriptan Teva | Zomig</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zomig | Zomig od</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan actavis | Zolmitriptan helvepharm | Zolmitriptan mepha | Zolmitriptan sandoz | Zolmitriptan spirig | Zolmitriptan zentiva | Zomig | Zomig oro</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Heng li an | Ka qu | Shu fu lai | Tian shu | Tuo fu ning | Zomig</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zolnox | Zomig</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan actavis | Zomig</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ascotop | Zolmitriptan 1a pharma | Zolmitriptan al | Zolmitriptan CT | Zolmitriptan glenmark | Zolmitriptan hexal | Zolmitriptan hormosan | Zolmitriptan neuraxpharm | Zolmitriptan Ratiopharm | Zolmitriptan stada | Zomig | Zomigoro</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zomigon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Zolmigren | Zolmitriptan 1a pharma | Zolmitriptan aurobindo disper | Zolmitriptan mylan | Zomig</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amigrawest | Antimigrozan | Azolmigra | No migrain z | No migran z | Solpadol | Zomig</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Flezol | Zolmitriptan aristo | ZOLMITRIPTAN Cinfa | Zolmitriptan combix | Zolmitriptan Flas Sandoz | Zolmitriptan Kern | Zolmitriptan kern pharma | Zolmitriptan mylan | Zolmitriptan Normon | Zolmitriptan Pharmagenus | Zolmitriptan QUALIGEN | Zolmitriptan Ranbaxy | Zolmitriptan Ratiopharm | Zolmitriptan stada | Zolmitriptan Tecnimede | Zolmitriptan Teva | Zolmitriptan viso pharmaceutics | Zomig</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zolmistad | Zolmitriptan actavis | Zolmitriptan sandoz | Zolmitriptan stada | Zolmitriptan Teva | Zomig</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan actavis | Zolmitriptan arrow | Zolmitriptan biogaran | Zolmitriptan Cristers | Zolmitriptan eg | Zolmitriptan Evolupharm | Zolmitriptan Myl | Zolmitriptan mylan | Zolmitriptan sandoz | Zolmitriptan Teva sante | Zolmitriptan Zydus | Zomig | Zomigoro</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zomigon</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Pms zolmitriptan | Zomig</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zomig | Zomig rapimelt</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Zolmist | Zolpax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Headzol | Zolmitriptan actavis | Zolmitriptan aurobindo | Zolmitriptan doc generici | Zolmitriptan mylan | Zomig</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Zomig | Zomig rm</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Zolan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan arrow | Zolmitriptan biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zolmist | Zolmitriptan 1a pharma | Zolmitriptan al | Zolmitriptan stada | Zomig | Zomig nasal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan eg | Zomig</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan arrow | Zolmitriptan hexal | Zomig</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Demitrip | Dozol | Magoz | Nurasense | Zomig</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan actavis | Zolmitriptan cf | Zolmitriptan mylan | Zolmitriptan pch | Zolmitriptan sandoz | Zomig</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan sandoz | Zomig</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Limigzol | Mignor | Triptan | Xoming | Zintin | Ziptan | Zolmipen | Zolmiton | Zolmitra | Zolmiwin | Zolon | Zomig | Zominat | Zomoz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zolmiles | Zolmitriptan stada | Zomig</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan odt | Zomig | Zomig-Zmt</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptano actavis | Zolmitriptano Aurovitas | Zolmitriptano Ciclum | Zolmitriptano Generis | Zolmitriptano labesfal | Zolmitriptano Vitalion | Zolmitriptano zentiva | Zomig</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zolmigaran | Zomig</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan actavis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Migrepam | Zolmitriptan sz | Zomig</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan 2care4 | Zolmitriptan actavis | Zolmitriptan arrow | Zolmitriptan Ebb | Zolmitriptan jubilant | Zolmitriptan orifarm | Zolmitriptan stada | Zolmitriptan Teva | Zomig | Zomig nasal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zolmitriptan Teva | Zomig</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Gravis | Zomig</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Rapimig | Xsenza | Zolmigren | Zomig</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Zomigon</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zomig</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zolmifor odt | Zomig</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet</i>
<i>Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33730376">
<a name="33730376"></a>Amundsen S, Nordeng H, Fuskevåg OM, Nordmo E, Sager G, Spigset O. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. <i>Basic Clin Pharmacol Toxicol</i>. 2021;128(6):795-804. doi:10.1111/bcpt.13579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/33730376/pubmed" id="33730376" target="_blank">33730376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10802793">
<a name="10802793"></a>Bahra A, Gawel MJ, Hardebo JE, Millson D, Breen SA, Goadsby PJ. Oral zolmitriptan is effective in the acute treatment of cluster headache. <i>Neurology</i>. 2000;54(9):1832-1839.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/10802793/pubmed" id="10802793" target="_blank">10802793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24848613">
<a name="24848613"></a>Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. <i>Cochrane Database Syst Rev</i>. 2014;2014(5):CD008616. doi:10.1002/14651858.CD008616.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/24848613/pubmed" id="24848613" target="_blank">24848613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33852763">
<a name="33852763"></a>Bjørk MH, Kristoffersen ES, Tronvik E, Egeland Nordeng HM. Management of cluster headache and other trigeminal autonomic cephalalgias in pregnancy and breastfeeding. <i>Eur J Neurol</i>. 2021;28(7):2443-2455. doi:10.1111/ene.14864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/33852763/pubmed" id="33852763" target="_blank">33852763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW and Shannon M, “The Serotonin Syndrome,” <i>N Engl J Med</i>, 2005, 352(11):1112-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16966497">
<a name="16966497"></a>Cittadini E, May A, Straube A, Evers S, Bussone G, Goadsby PJ. Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study. <i>Arch Neurol</i>. 2006;63(11):1537-1542.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/16966497/pubmed" id="16966497" target="_blank">16966497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15697326">
<a name="15697326"></a>Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. <i>CNS Drugs</i>. 2005;19(2):125-136. doi:10.2165/00023210-200519020-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/15697326/pubmed" id="15697326" target="_blank">15697326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11972576">
<a name="11972576"></a>Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. <i>Cephalalgia</i>. 2002;22(2):101-106. doi:10.1046/j.1468-2982.2002.00319.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/11972576/pubmed" id="11972576" target="_blank">11972576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15663607">
<a name="15663607"></a>Gawel M, Aschoff J, May A, Charlesworth BR; REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE study. <i>Headache</i>. 2005;45(1):7-16. doi:10.1111/j.1526-4610.2005.05004.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/15663607/pubmed" id="15663607" target="_blank">15663607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21751829">
<a name="21751829"></a>Källén B, Nilsson E, and Otterblad Olausson P, "Delivery Outcome After Maternal Use of Drugs for Migraine: A Register Study in Sweden," <i>Drug Saf</i>, 2011, 34(8):691-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/21751829/pubmed" id="21751829" target="_blank">21751829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-May.1">
<a name="May.1"></a>May A. Cluster headache: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32017486">
<a name="32017486"></a>National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. <a href="https://www.ncbi.nlm.nih.gov/books/NBK553317/pdf/Bookshelf_NBK553317.pdf" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK553317/pdf/Bookshelf_NBK553317.pdf</a> Published December 17, 2021. Accessed November 7, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/32017486/pubmed" id="32017486" target="_blank">32017486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22946832">
<a name="22946832"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng HM, "Errata in 'Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study,'" <i>Headache</i>, 2012, 52(8):1319-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/22946832/pubmed" id="22946832" target="_blank">22946832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132339">
<a name="20132339"></a>Nezvalová-Henriksen K, Spigset O, and Nordeng H, "Triptan Exposure During Pregnancy and the Risk of Major Congenital Malformations and Adverse Pregnancy Outcomes: Results From the Norwegian Mother and Child Cohort Study," <i>Headache</i>, 2010, 50(4):563-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/20132339/pubmed" id="20132339" target="_blank">20132339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23884894">
<a name="23884894"></a>Nezvalová-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. <i>Eur J Epidemiol</i>. 2013;28(9):759-769. doi: 10.1007/s10654-013-9831-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/23884894/pubmed" id="23884894" target="_blank">23884894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17724283">
<a name="17724283"></a>Rapoport AM, Mathew NT, Silberstein SD, et al. Zolmitriptan nasal spray in the acute treatment of cluster headache: a double-blind study. <i>Neurology</i>. 2007;69(9):821-826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/17724283/pubmed" id="17724283" target="_blank">17724283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9371896">
<a name="9371896"></a>Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. <i>Neurology</i>. 1997;49(5):1210-1218. doi:10.1212/wnl.49.5.1210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/9371896/pubmed" id="9371896" target="_blank">9371896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432623">
<a name="27432623"></a>Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: the American Headache Society evidence-based guidelines. <i>Headaches</i>. 2016;56(7):1093-1106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/27432623/pubmed" id="27432623" target="_blank">27432623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35296510">
<a name="35296510"></a>Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. <i>BMJ</i>. 2022;376:e059577. doi:10.1136/bmj-2020-059577<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/35296510/pubmed" id="35296510" target="_blank">35296510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, et al, “Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,”<i> Neurology</i>, 2012, 78(17):1337-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28758416">
<a name="28758416"></a>Spielmann K, Kayser A, Beck E, Meister R, Schaefer C. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort study. <i>Cephalalgia</i>. 2018;38(6):1081-1092. doi: 10.1177/0333102417724152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/28758416/pubmed" id="28758416" target="_blank">28758416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15581383">
<a name="15581383"></a>Spierings EL, Rapoport AM, Dodick DW, Charlesworth B. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. <i>CNS Drugs</i>. 2004;18(15):1133-1141. doi:10.2165/00023210-200418150-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/15581383/pubmed" id="15581383" target="_blank">15581383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the global campaign against headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33948734">
<a name="33948734"></a>Suri H, Ailani J. Cluster headache: a review and update in treatment. <i>Curr Neurol Neurosci Rep</i>. 2021;21(7):31. doi:10.1007/s11910-021-01114-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/33948734/pubmed" id="33948734" target="_blank">33948734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18788838">
<a name="18788838"></a>Tuchman MM, Hee A, Emeribe U, et al, “Oral Zolmitriptan in the Short-Term Prevention of Menstrual Migraine: A Randomized, Placebo-Controlled Study,” <i>CNS Drugs</i>, 2008, 22(10):877-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/18788838/pubmed" id="18788838" target="_blank">18788838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32886179">
<a name="32886179"></a>Viard D, Gérard A, Tahiri J, Tieulié N, Van Obberghen E, Drici MD. Triptan overuse during pregnancy: a possible cause of placental hypoperfusion. <i>Eur J</i>
<i>Clin Pharmacol</i>. 2021;77(2):269-270. doi:10.1007/s00228-020-02991-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/32886179/pubmed" id="32886179" target="_blank">32886179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23968886">
<a name="23968886"></a>Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society guideline: acute drug therapy for migraine headache. <i>Can J Neurol Sci</i>. 2013;40(5)(suppl 3):S1-S80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/zolmitriptan-drug-information/abstract-text/23968886/pubmed" id="23968886" target="_blank">23968886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zomig.1">
<a name="Zomig.1"></a>Zomig and Zomig-ZMT (zolmitriptan) [prescribing information]. Bridgewater, NJ: Amneal Specialty; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zomig.2">
<a name="Zomig.2"></a>Zomig nasal spray (zolmitriptan) [prescribing information]. Bridgewater, NJ: Amneal Specialty, a division of Amneal Pharmaceuticals LLC; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jubilant.1">
<a name="Jubilant.1"></a>Zolmitriptan tablets [prescribing information]. Salisbury, MD: Jubilant Cadista Pharmaceuticals, Inc; December 2014.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10233 Version 387.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
